Update on the Phase I/II BRUIN study

BRUIN study cohort update: pirtobrutinib for patients with MCLПодробнее

Updates from the BRUIN study – long-term safety of pirtobrutinib in R/R MCLПодробнее

Updated results of Phase I/II BRUIN study: pirtobrutinib in covalent BTK inhibitor pretreated MCLПодробнее

Phase I/II BRUIN study: pirtobrutinib in patients intolerant to a covalent BTK inhibitorПодробнее

Advances in non-covalent BTK inhibitors for CLL: BRUIN study updateПодробнее

BRUIN study: updated two-year subgroup analysis of pirtobrutinib for BTKi pre-treated MCLПодробнее

Latest updates from the Phase I/II BRUIN studyПодробнее

Updated results from the BRUIN study: pirtobrutinib in the treatment of MCLПодробнее

Updates on the Phase I/II BRUIN study and the role of pirtobrutinib in MCLПодробнее

Updates from the Phase I/II BRUIN study: pirtobrutinib in CLLПодробнее